Chang Feng Pharmaceutical: The company's leading new inhaled nucleic acid drug development project was selected as the "Innovative Biopharmaceutical" project of the 2025 Jiangsu Province Science and Technology Major Special Project.

Changfeng Pharmaceutical announced that the company-led new inhaled nucleic acid drug development project has recently been selected as the "Innovative Biopharmaceutical" project of the 2025 Jiangsu Province Science and Technology Major Project. This project focuses on the key challenges of small nucleic acid drugs in pulmonary delivery, and is committed to promoting the translational research and preclinical development of inhaled nucleic acid candidate drugs. The project plans to support the research and development of inhaled nucleic acid candidate drugs for major respiratory diseases. The scope of work includes optimization of delivery systems, pharmaceutics and process development, preclinical studies, and preparation of applications for new drug clinical trials.